statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Nuvation Bio Announces Updates and Upcoming Presentations for its ROS1 Inhibitor, Taletrectinib

Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced multiple updates for its taletrectinib...

Innovent Announces TaletrectinibROS1 InhibitorUpdated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual Meeting

Innovent Announces TaletrectinibROS1 InhibitorUpdated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual Meeting Innovent Announces...

Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of TaletrectinibROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting

Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of TaletrectinibROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting Innovent Announces Data from Pivotal Phase...

Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual Meeting

Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, announced that results from the pivotal Phase 2 TRUST-I...

Nuvation Bio to Present at the Jefferies Global Healthcare Conference

Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic...

Nuvation Bio Reports First Quarter 2024 Financial Results and Provides Business Update

Nuvation Bio Inc. (NYSE: NUVB), a late-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates...

Nuvation Bio Completes Acquisition of AnHeart Therapeutics

Commit To Buy Nuvation Bio At $2.50, Earn 17.2% Annualized Using Options

Investors eyeing a purchase of Nuvation Bio Inc (NUVB) shares, but tentative about paying the going market price of 3.50/share, might benefit from considering selling puts among the alternative...

Nuvation Bio: Strong Buy Off The Acquisition Of A Late-Stage Lung Cancer Candidate

Nuvation Bio: Strong Buy Off The Acquisition Of A Late-Stage Lung Cancer Candidate...

Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.

Volume	1.24M
52-Wk High	$4.16
52-Wk Low	$0.95

NUVB Nuvation Bio Inc - Ordinary Shares - Class A

About

Feed

News

Sentiment

Earnings

Fundamentals